CN202676698U - Clotting time detection device - Google Patents
Clotting time detection device Download PDFInfo
- Publication number
- CN202676698U CN202676698U CN 201220200292 CN201220200292U CN202676698U CN 202676698 U CN202676698 U CN 202676698U CN 201220200292 CN201220200292 CN 201220200292 CN 201220200292 U CN201220200292 U CN 201220200292U CN 202676698 U CN202676698 U CN 202676698U
- Authority
- CN
- China
- Prior art keywords
- blood
- clotting time
- duct
- unit
- time pick
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010053567 Coagulopathies Diseases 0.000 title claims abstract description 46
- 230000035602 clotting Effects 0.000 title claims abstract description 46
- 238000001514 detection method Methods 0.000 title abstract description 17
- 230000017531 blood circulation Effects 0.000 claims abstract description 21
- 238000010241 blood sampling Methods 0.000 claims abstract description 17
- 239000004033 plastic Substances 0.000 claims abstract description 11
- 229920003023 plastic Polymers 0.000 claims abstract description 11
- 230000001934 delay Effects 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 7
- 239000011521 glass Substances 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 2
- 239000000835 fiber Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 239000005060 rubber Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 63
- 239000008280 blood Substances 0.000 abstract description 63
- 230000023555 blood coagulation Effects 0.000 abstract description 22
- 239000011148 porous material Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 description 37
- 238000012360 testing method Methods 0.000 description 15
- 230000015271 coagulation Effects 0.000 description 10
- 238000005345 coagulation Methods 0.000 description 10
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 8
- 108010000499 Thromboplastin Proteins 0.000 description 8
- 102000002262 Thromboplastin Human genes 0.000 description 8
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 7
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 7
- 239000003114 blood coagulation factor Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000007689 inspection Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 208000014759 blood platelet disease Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The utility model provides a clotting time detection device. The clotting time detection device comprises a plastic shell (1). A pore passageway (2) is arranged inside the shell (1). The clotting time detection device is characterized in that at least one component (3) used for postponing blood flowing is arranged inside the pore passageway (2), and the pore passageway (2) comprises a first port (4) provided with an opening in the outside surface of the shell (1) and used to form a blood sampling end and a second port (5) used to be connected with a blood flow pushing device and a pressure sensor. The clotting time detection device can measure whole blood clotting time simply, quickly and accurately, and can be used to evaluate a human body clotting function.
Description
Technical field
The utility model belongs to medical instruments field, is specifically related to a kind of clotting time pick-up unit, and particularly a kind of human body peripheral blood that gathers carries out the device that the clotting time detects.
Background technology
The normal human has perfect blood coagulation and anti-freezing function, and the anticoagulation system of human body can be kept blood and be flow state, prevents that the thrombus that forms in the body from continuing to extend and enlarge, thereby guarantees normal blood circulation, to partes corporis humani position supply blood; But when vascular injury, the human body blood coagulation system can form thrombus rapidly and stop blooding.The blood coagulation system of human body, anticoagulation system continue to keep mobile equilibrium, to guarantee normal blood flow, prevent hemorrhage or too much thrombosis.
When wound appearred in human body, blood can autocoagulation be bled profusely avoiding.Medically, the blood clotting ability of human body is to using blood-clotting agent and anticoagulation medicine to have directive significance.The heparin metering of using when for example the coagulation function of human body power is with operation has directive significance.Therefore, there is widely demand in the inspection of human body blood coagulation mechanism at medical domain.
The clotting time inspection is clinical common inspection item, has very important clinical meaning, factor all can cause cruor time extending to comprise that blood vessel itself is unusual, blood platelet disorders, clotting factor are unusual etc., and DIC, Pre-thrombosis State and thrombotic diseases can cause the clotting time to shorten.The coagulation function inspection is the important means of diagnosis of hematologic diseases, checks patient's coagulation function before the art, can effectively prevent from reaching postoperative and the fortuitous events such as haemophilia occur in art, thereby obtain best surgical effect.
At present, the method that the clinical employing clotting time checks comprises clotting time detection, activated clotting time (activated clotting time, ACT) method and the detection of activated partial thromboplastin time method etc., in order to assess the coagulation function of human body.
Whether the clotting time (CT) in the time that ectogensis solidifies, mainly is that whether various clotting factor functions are normal in the mensuration intrinsic coagulation approach after referring to that blood leaves blood vessel, perhaps have anticoagulant substances to increase.Different according to Specimen origin, the coagulation time test method is divided into capillary blood sampling and venous blood collection method.Capillary blood sampling can adopt slide method or capillary method to measure.Because blood collection procedure easily sneaks into more tissue fluid, even thereby the intrinsic coagulation factor lack, extrinsic coagulation also still occurs, make and should unusual result become normally, cause this method much less responsive, loss reaches 95%, therefore belong to superseded method.Therefore the venous blood collection method judges that the accuracy of endogenous deficiency of coagulation factors is higher than capillary blood sampling owing to the less tissue fluid of sneaking in the blood.3 kinds of concrete operation methods are arranged at present: (1) common test tube method (Lee-White method): this method sensitivity is not high, is tending towards at present superseded yet.(2) silicone tube method (SCT): the determination step of this law and common test tube method is basic identical, and unique difference is to adopt the test tube that scribbles silicone oil.Because the silicone tube inwall is difficult for making inwall clotting factor contact activation, therefore the clotting time is longer than common test tube method.
Activated clotting time (activated clotting time, ACT) method is to add white bole partial thromboplastin suspension in whole blood to be checked, the proconvertin of first fully contact, activation activation system, XI etc., and for the blood coagulation reaction provides abundant catalytic surface, thereby improved the accuracy of test.The ACT method also is one of better means of monitoring extracorporal circulatory system heparin consumption.
The activated partial thromboplastin time method refers in anticoagulate plasma, adds activation contact factor activator and the partial thromboplastin (replacing hematoblastic phosphatide) of capacity, adds an amount of calcium ion again and can satisfy endogenous anticoagulant full terms.Namely be called activated partial thromboplastin time (APTT) from the adding calcium ion to the required time of the clotting of plasma.The length of APTT has reflected in the blood plasma level of factor, fibrinogen and factor V, X in the endogenous blood coagulation system clotting factor common pathway.This test is at present the most frequently usedly to have a whether normal shaker test of the endogenous blood coagulation system of highly sensitive inspection.
At present, common test tube method and silicone tube method measure the clotting time because error is large, has approached and has eliminated.And the hemostatic function of body is to be finished by the acting in conjunction of blood platelet, blood coagulation system, fibrinolytic system and blood vessel endothelium system etc., therefore, activated clotting time method or all there is certain shortcoming in the activated partial thromboplastin time method: (1) vein ischemic, amount for taking blood is many; (2) blood coagulation of blood of human body comprises series reaction, relates to the several factors such as blood platelet, clotting factor, fibrin ferment, is thrombin activity and activated clotting time method and activated partial thromboplastin time method detect, can not reflect the coagulation function of whole blood; (3) activated clotting time method and activated partial thromboplastin time method complex operation need the professional to implement, and blood sampling and mensuration personnel all should be skilled in technique, otherwise easily cause error; (4) minute is long, can not provide at short notice the result.Therefore, exploitation method simple, quick and energy Accurate Determining whole blood coagulation time has important clinical meaning.
Each discloses a kind of blood clotting checkout equipment US Patent No. 5302348 and US5504011, and this inspection machine comprises the instrument of detection and the consumptive material of detection.Wherein, have two on the detection consumptive material of US Patent No. 5302348 and detect duct and droplet of blood hand-hole, the light sensor equipment that comprises two pneumatic pumps on the detecting instrument and detect the blood position.Have many check ducts and droplet of blood hand-hole on the laboratory consumables of US Patent No. 5504011, come that with a pneumatic pump blood in a plurality of ducts is carried out push-and-pull on the checkout equipment and drive.In order to reach test effect, in every duct the flow locations that light sensor detects blood is set.By driving device for step-by-step, drive blood and in detecting card, flow, in the duct, to flow through to the needed time of set a distance by the light sensor monitoring of blood, this time is during greater than threshold value, judges that blood arrives to condense.
The disclosed clotting time detection method of above-mentioned United States Patent (USP) and equipment still have following defective: when getting blood, the blood of finger need to splash in the special blood sampling device (1), length consuming time, and amount for taking blood is many; (2) blood sampling device is complicated, gets the blood process and has the factor that much easily excites blood coagulation, easily causes the variation in clotting time, can cause larger resultant error; (3) generation of whole blood fluid column is condensed in the duct, thereby changes flowing velocity, and required time is longer; (4) can measure at heating arrangement after getting blood, not consider to get the time that temperature in the blood process also may affect blood coagulation but; (5) testing process is complicated, and test card and equipment making cost are high.
The utility model content
The purpose of this utility model is to provide a kind of clotting time pick-up unit, and this pick-up unit can be simply, quick, Accurate Determining whole blood coagulation time, and then is used for estimating the human body coagulation function.
Be used for realizing that the technical scheme of above-mentioned purpose is as follows:
A kind of clotting time pick-up unit, this device comprises plastic casing (1), the inside of described housing (1) arranges duct (2), inside, described duct (2) arranges at least one element that delays blood flow (3), and described duct (2) comprise that also being opened on housing (1) outside surface is used to form the first port (4) that blood sampling is held, and are opened on the second port (5) that housing (1) outside surface is used for connecting blood flow pusher and pressure transducer.
One end in described duct (2) forms the blood sampling end, stings into small wound with sharp instrument at finger tip first during blood sampling, and after peripheral blood flowed out the formation drop of blood, the end of will taking a blood sample contacted with drop of blood.Because plastics are that the aperture of blood infiltrating material and blood sampling end is less, blood is by in the automatic suction passage of syphonic effect.
The temperature of body inner blood is generally about 37 ℃, the viscosity temperature influence of blood is very large, in the room temperature situation, adopt the blood sample of glass heparin tube collection to turn cold rapidly, the indexs such as the viscosity of blood, thrombin activity, biologically active pdgf can change accordingly, finally can affect the result of mensuration.In order to eliminate the impact of temperature, pick-up unit of the present utility model is selected plastic material, and its heat transfer property is poor, can eliminate the adverse effect of temperature.Specifically, before the blood sampling, pick-up unit can place first thermostat insulation a period of time of constant temperature oven for example to take out again, because the dissipation of heat of plastic plate is slow, pick-up unit can keep certain temperature when getting blood, the blood sample of avoiding gathering turns cold rapidly, thereby guarantees that testing result is subjected to the impact of room temperature less.
Behind the blood sample collection, the external blood flow pusher of duct one end drives blood sample and flows in the duct.Described blood flow pusher can be air pump, membrane pump or stepper motor pump etc.The blood flow pusher allows blood constantly flow in the duct by repeatedly the duct being filled with gas and gas bleeding process.Blood condenses after leaving human body, finally forms the blood clotting piece.By being connected in the pressure in the pressure transducer detection duct on the port of duct.When the pressure rise in the duct arrived predetermined threshold value, the expression blood clotting can calculate blood coagulating time.
Preferably, the duct that diminishes for xsect of the described element (3) that delays blood flow.Perhaps, preferably, the described element (3) that delays blood flow is obstacles, and for example with the obstacles of at least one through hole, the concrete form of obstacles can be referring to Fig. 3 A-F.One or more snippets of the duct of described pick-up unit can be designed as the duct that xsect diminishes, also can be in the duct place or many places obstacles porose and that blood can flow through is set, thereby accelerate solidifying of blood, improve detection efficiency.The described material that delays the element (3) of blood flow can be plastics, rubber, glass, metal, fiber or nylon etc.
Described housing (1) can be designed to various shapes as required.Preferably, described housing (1) is sheet; More preferably, described housing (1) be sheet cube and maximum length less than 20 centimetres, breadth extreme is less than 10 centimetres, maximum ga(u)ge is less than 1 centimetre.
Preferably, the xsect of described duct (2) can be the various shapes such as circular, square, rectangle or ellipse.More preferably, the full-size of the xsect of described duct (2) is not more than 10 square millimeters.
Preferably, described duct (2) inner xsect that also arranges becomes large chamber (6), is used for making the to-and-fro movement of blood more steady.
Compared with prior art, the utlity model has following advantage:
(1) this pick-up unit is simple in structure, gets blood by finger, and amount for taking blood is few, and simple and fast also can quantitatively be taken a blood sample.
(2) clotting time of this detection means measure is the clotting time of whole blood, more can directly reflect the coagulation function of human body comprehensively.
(3) this pick-up unit is selected plastic material, its heat transfer property is poor, can put into first thermostat insulation a period of time before the blood sampling takes out again, because the dissipation of heat of plastic plate is slow, pick-up unit can keep certain temperature when getting blood, the blood sample of avoiding gathering turns cold rapidly, thereby guarantees the less impact that is subjected to room temperature of result.
(4) in order to reduce Measuring Time, one or more snippets of the duct of pick-up unit can be designed as the duct that xsect diminishes, also can be in the duct place or many places place the obstacles that one or more porose blood can flow through.When blood during back and forth by the duct that attenuates or obstacles, can increase friction, make the time shorten of blood clotting, thereby reduce the time of measuring.
(5) pick-up unit is designed to laminarly, can easily pick-up unit be inserted in the special heat-preserving equipment, also can insert easily in the checkout equipment of design, for example detects by light, and the methods such as electromagnetic field detection are implemented further to detect.
Description of drawings
Describe the utility model in detail below in conjunction with accompanying drawing, the Reference numeral that adopts in the accompanying drawing represents respectively:
1 is plastic casing; 2 is the duct; 3 for delaying the element of blood flow; 4 is the first port; 5 is the second port; 6 is chamber.
Fig. 1 shows the structure of embodiment 1 described clotting time pick-up unit;
Fig. 2 shows the structure of embodiment 2 described clotting time pick-up units;
Fig. 3 A-F shows the structure that delays the element (3) of blood flow in the embodiment 3 described clotting time pick-up units.
Embodiment
Further describe the present invention below in conjunction with specific embodiment, advantage and disadvantage of the present invention will be more clear along with description.But these embodiment only are exemplary, scope of the present invention are not consisted of any restriction.It will be understood by those skilled in the art that lower without departing from the spirit and scope of the present invention and can make amendment or replace the details of technical solution of the present invention and form, but these modifications and replacing all fall within the scope of protection of the present invention.
See Fig. 1, the duct of clotting time pick-up unit (2) are the craspedodrome duct, and an end is for forming first port (4) of blood sampling end.The second port (5) communicates with atmosphere, is used for taking external air pump behind the blood, and air pump allows blood constantly flow in the duct by repeatedly inflating and deflation course.At this moment, blood begins to condense, form the blood clotting piece, when the element (3) of coagula by delaying blood flow---during duct that xsect diminishes, be subject to certain resistance, this moment, air pump continued the pull operation is carried out in the duct, and the pressure in the duct can rise, and carried out pressure detection in the duct by being connected in pressure transducer on the air pump.
Pressure in the duct changes according to Bernoulli equation:
Wherein: P is pressure P
aZ is the average velocity that flows through on the section; υ flows through the average velocity on the section; The density of ρ fluid; P/ ρ is the pressure potential of unit mass fluid; The position potential energy of zg unit mass fluid; V
2The kinetic energy of/2 unit mass fluids; h
wThe g energy loss; Hg is extraneous acting; a
1, a
2The correction factor of introducing owing to velocity distribution is inhomogeneous.Because the duct is a=1.05 ~ 1.10 narrowing intra-zone generation turbulent flow through testing its numerical value.
Above Bernoulli equation through obtaining blood samples mobile pressure loss of being produced in the duct behind the abbreviation is
。Wherein parameter ε and duct internal diameter scale down exist relatedly, and pusher is when carrying out pusher, and one section in duct links to each other with atmosphere, and one section links to each other with pump, and the pressure differential of generation is
, its middle term
Relevant with cell walls and orifice throat length, in measurement, can ignore the pressure variable effect.Its middle term
Relevant with inlet angle and the duct constriction regional diameter constriction ratio in constriction zone, duct, the numeric reference table that obtains ε through test is as follows:
After measuring, obtain the corresponding table of aperture convergent-divergent multiple and resistance coefficient variation
Also there are correlativity in entrance angle of inclination and the pressure loss in its constriction duct, obtain tables of data through experiment as follows:
Pressure change mainly by
Formula determines, when the duct is blocked, the inlet angle that the zone is narrowed in the duct changes, and narrows regional diameter ratio with zone, normal duct and change Δ P
fChange.Obtain pressure Δ P through test
fChange when reaching 1500pa to 2000pa, confirm that the duct inwall blocks.
See Fig. 2, the duct of clotting time pick-up unit (2) are the U-shaped duct, and an end is for forming first port (4) of blood sampling end, and the second port (5) communicates with atmosphere.There is the element (3) that delays blood flow in the duct, i.e. the sector hole duct that directly attenuates.When blood back and forth during the duct by attenuating, friction increases, and blood coagulation time is shortened.Operating process is with embodiment 1.
Embodiment 3:
The duct of clotting time pick-up unit (2) is the U-shaped duct, and an end is for forming first port (4) of blood sampling end, and the second port (5) communicates with atmosphere.There is the element (3) that delays blood flow in the duct except comprising that a sector hole directly attenuates the duct, and also a place or many places arrange the obstacles that porose blood can flow through in the duct, and concrete form is seen Fig. 3 A-F, thereby accelerates solidifying of blood, improves detection efficiency.Other structures and operating process are with embodiment 2.
Claims (10)
1. clotting time pick-up unit, this device comprises plastic casing (1), the inside of described housing (1) arranges duct (2), it is characterized in that, inside, described duct (2) arranges at least one element that delays blood flow (3), and described duct (2) comprise that also being opened on housing (1) outside surface is used to form the first port (4) that blood sampling is held, and are opened on the second port (5) that housing (1) outside surface is used for connecting blood flow pusher and pressure transducer.
2. clotting time pick-up unit according to claim 1 is characterized in that, the duct that the described element (3) that delays blood flow diminishes for xsect.
3. clotting time pick-up unit according to claim 1 is characterized in that, the described element (3) that delays blood flow is obstacles, for example with the obstacles of at least one through hole.
4. clotting time pick-up unit according to claim 1 is characterized in that, the described material that delays the element (3) of blood flow is plastics, rubber, glass, metal, fiber or nylon.
5. each described clotting time pick-up unit in 4 according to claim 1 is characterized in that, described housing (1) is sheet.
6. each described clotting time pick-up unit in 4 according to claim 1 is characterized in that, described housing (1) be sheet cube and maximum length less than 20 centimetres, breadth extreme is less than 10 centimetres, maximum ga(u)ge is less than 1 centimetre.
7. each described clotting time pick-up unit in 4 according to claim 1 is characterized in that, the xsect of described duct (2) is circular, square, rectangle or ellipse.
8. each described clotting time pick-up unit in 4 according to claim 1 is characterized in that, the full-size of the xsect of described duct (2) is not more than 10 square millimeters.
9. each described clotting time pick-up unit in 4 according to claim 1 is characterized in that, described duct (2) inner xsect that also arranges becomes large chamber (6).
10. each described clotting time pick-up unit in 4 according to claim 1 is characterized in that, described blood flow pusher is air pump, membrane pump or stepper motor pump.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201220200292 CN202676698U (en) | 2012-05-04 | 2012-05-04 | Clotting time detection device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201220200292 CN202676698U (en) | 2012-05-04 | 2012-05-04 | Clotting time detection device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN202676698U true CN202676698U (en) | 2013-01-16 |
Family
ID=47497597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201220200292 Expired - Lifetime CN202676698U (en) | 2012-05-04 | 2012-05-04 | Clotting time detection device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN202676698U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103383391A (en) * | 2012-05-04 | 2013-11-06 | 北京尚位非凡医药科技有限公司 | Detection apparatus for blood clotting time |
| CN111912737A (en) * | 2019-05-07 | 2020-11-10 | 重庆南方数控设备有限责任公司 | Method and device for detecting solidification of viscoelastic solution |
-
2012
- 2012-05-04 CN CN 201220200292 patent/CN202676698U/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103383391A (en) * | 2012-05-04 | 2013-11-06 | 北京尚位非凡医药科技有限公司 | Detection apparatus for blood clotting time |
| CN103383391B (en) * | 2012-05-04 | 2015-07-08 | 北京尚位非凡医药科技有限公司 | Detection apparatus for blood clotting time |
| CN111912737A (en) * | 2019-05-07 | 2020-11-10 | 重庆南方数控设备有限责任公司 | Method and device for detecting solidification of viscoelastic solution |
| CN111912737B (en) * | 2019-05-07 | 2023-09-26 | 重庆南方数控设备有限责任公司 | Method and device for detecting solidification of viscoelastic solution |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103383391B (en) | Detection apparatus for blood clotting time | |
| JP5572868B2 (en) | Apparatus and method for measuring the coagulation characteristics of a test liquid | |
| CN110691972B (en) | Disposable system for hemostatic function analysis | |
| Herring et al. | Diagnostic approach to small animal bleeding disorders | |
| US3951606A (en) | Apparatus for prothrombin testing | |
| Prisco et al. | Point-of-care testing of hemostasis in cardiac surgery | |
| US20230158498A1 (en) | Methods And Devices For Detection Of Anticoagulants In Plasma And Whole Blood | |
| US12019064B2 (en) | Coagulation test device, system, and method of use | |
| US20060269978A1 (en) | Method and device for monitoring platelet function | |
| CN202676698U (en) | Clotting time detection device | |
| CN106771108B (en) | Method and device for automatically acquiring thromboelastography | |
| JP2008185564A (en) | Blood coagulation test method and blood coagulation test device | |
| WO2020190266A1 (en) | Coagulation test device, system, and method of use | |
| KR101363812B1 (en) | Bleeding time measurement apparatus and method by using blood migration ratio | |
| US20210260589A1 (en) | Method and Apparatus for Measuring Blood Coagulation | |
| Scarlatescu et al. | Validation of the time to attain maximal clot amplitude after reaching maximal clot formation velocity parameter as a measure of fibrinolysis using rotational thromboelastometry and its application in the assessment of fibrinolytic resistance in septic patients: a prospective observational study: communication from the ISTH SSC Subcommittee on Fibrinolysis | |
| Eugster et al. | Viscosity measurements on very small capillary blood samples | |
| Phillips et al. | Low‐molecular‐weight heparin may alter point‐of‐care assay for international normalized ratio | |
| Saxena et al. | Laboratory studies in coagulation disorders | |
| CN206281858U (en) | A kind of device of automatic acquisition thrombelastogram | |
| CN111983207A (en) | Whole blood quality control product of thromboelastogram instrument and preparation method | |
| Summers et al. | In‐House Evaluation of Hemostasis | |
| US20070285651A1 (en) | Methods and devices for measuring sample coagulation | |
| Uttam | A Comparative Study of Inr Ratio Between Automatic (Acl Elite Pro) And Semiautomatic (Erba) Coagulometers | |
| Paarup et al. | Performance characteristics of thromboelastometry assays using incompletely filled and prolonged stored samples |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20130116 |